5-year results of a randomized comparison of XIENCE v everolimus-eluting and TAXUS paclitaxel-eluting stents: Final results from the SPIRIT III trial (Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions)

导出原文传递

翻译打印收藏纠错

作者： Gada,H. ^[1] ; Kirtane,A.J. ^[2] ; Newman,W. ^[3] ; Sanz,M. ^[4] ; Hermiller,J.B. ^[5] ; Mahaffey,K.W. ^[6] ; Cutlip,D.E. ^[7] ; Sudhir,K. ; Hou,L. ; Koo,K. ; Stone,G.W.

作者单位： Heart Center of Indiana, Indianapolis, IN, United States ^[1] Wake Medical Center, Raleigh, NC, United States ^[2] Columbia University Medical Center, New York-Presbyterian Hospital, Cardiovascular Research ^[3] Abbott Vascular, Santa Clara, CA, United States ^[4] St. Patrick Hospital, Missoula, MT, United States ^[5] Duke Clinical Research Institute, Durham, NC, United States ^[6] Harvard Clinical Research Institute, Boston, MA, United States ^[7]

关键词 coronary artery disease drug-eluting stent(s)in-stent restenosis stent thrombosis target vessel failure

发布时间 2014-05-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交